Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 20
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Beam Therapeutics Inc
BEAM
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$24.19
0.72
3.07%
Ult. Agg.: Oct 20, 8:48 AM
$24.00
0.53
2.26%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Beam Therapeutics Financials
Beam Therapeutics (BEAM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Beam Therapeutics Q2 EPS $(1.18) Misses $(1.11) Estimate, Sales $490.000K Miss $16.370M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.11) by 6.31 percent. This is a 18 percent decrease over losses of $(1.00) per share from
Benzinga Newsdesk
PRO
Beam Therapeutics Q1 EPS $(0.91) Beats $(1.09) Estimate, Sales $31.738M Beat $10.977M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.09) by 16.51 percent. This is a 26.02 percent increase over losses of $(1.23) per share from
Benzinga Newsdesk
PRO
Beam Therapeutics Q4 Adj. EPS $(0.10) Beats $(0.99) Estimate, Sales $114.109M Beat $12.567M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.99) by 89.92 percent. This is a 90.83 percent increase over losses of $(1.09) per share from
Benzinga Newsdesk
Earnings Summary: Beam Therapeutics Q4
Benzinga Insights
Earnings Scheduled For February 24, 2026
Benzinga Insights
PRO
Beam Therapeutics Q3 EPS $(1.10) Misses $(1.05) Estimate, Sales $9.698M Miss $12.368M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(1.05) by 5.16 percent. This is a 5.98 percent increase over losses of $(1.17) per share from
Benzinga Newsdesk
